Together, these data suggest that the addition of CD4+ T cell depletion to PD-L1 blockade therapy promotes the tumor infiltration of CD8+ T cells and the eradication of PD-L1+ immune cells in MCA38 tumors. This evidence concerns the gene CD8A and neoplasm.